Personalizing medicine for metastatic colorectal cancer: Current developments

doi:10.3748/wjg.v20.i30.10425

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 30

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7016)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

457

WORD

298

HTML

3583

Figures (1-1)

242

Tables (1-1)

194

Sum=4774

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1117

Download

1125

Sum=2242

Aug 14, 2014 (publication date) through Dec 31, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Aug 14, 2014; 20(30): 10425-10431
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10425

Open in New Tab Full Size Figure Download Figure

Figure 1 Exemplification of bevacizumab mechanisms of action, which acts by inhibiting the vascular endothelial growth factor family ligands to their receptors and thus blocking tumor angiogenesis. VEGF: Vascular endothelial growth factor; PlGF: Placental growth factor.

Citation: Marques AM, Turner A, de Mello RA. Personalizing medicine for metastatic colorectal cancer: Current developments. World J Gastroenterol 2014; 20(30): 10425-10431
URL: https://www.wjgnet.com/1007-9327/full/v20/i30/10425.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i30.10425